News


Tumor TARGET Prostate Cancer
Fri, 10 May 2013 14:27:00 GMT
A look at the following clinical trial: Tumor TARGET Prostate Cancer.


Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
Fri, 10 May 2013 14:25:00 GMT
A look at the following clinical trial: Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer.


Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Fri, 10 May 2013 14:23:00 GMT
A look at the following clinical trial: Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy.


Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer
Fri, 10 May 2013 14:20:00 GMT
A look at the following clinical trial: Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer.


Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Fri, 01 Mar 2013 11:00:00 GMT
A look at the following clinical trial: Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer.


BKM120 in Metastatic Castration-resistant Prostate Cancer
Mon, 31 Dec 2012 16:32:00 GMT
A look at the following clinical trial: BKM120 in Metastatic Castration-resistant Prostate Cancer.


Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer (MRSI+RRP)
Mon, 31 Dec 2012 16:29:00 GMT
A look at the following clinical trial: Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer (MRSI+RRP).


Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
Sat, 27 Oct 2012 18:34:00 GMT
A look at the following clinical trial: Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation.


Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
Sat, 27 Oct 2012 18:31:00 GMT
A look at the following clinical trial: Ipilimumab and GMCSF Immunotherapy for Prostate Cancer.


Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Sun, 02 Sep 2012 14:48:00 GMT
A look at the following clinical trial: Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer.


A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology
Sun, 02 Sep 2012 14:43:00 GMT
A look at the following clinical trial: A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology.


Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
Tue, 01 May 2012 13:52:00 GMT
A look at the following clinical trial: Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery.


Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Sun, 01 Apr 2012 15:50:00 GMT
A look at the following clinical trial: Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer.


Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Thu, 01 Mar 2012 11:00:00 GMT
A look at the following clinical trial: Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer.


STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial
Thu, 01 Mar 2012 11:00:00 GMT
A look at the following clinical trial: STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial.


Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Sun, 01 Jan 2012 18:59:00 GMT
A look at the following clinical trial: Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer.


The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
Sun, 01 Jan 2012 18:58:00 GMT
A look at the following clinical trial: The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer.


Genetic Risk Profiling in Patients With Prostate Carcinoma
Sun, 01 Jan 2012 18:56:00 GMT
A look at the following clinical trial: Genetic Risk Profiling in Patients With Prostate Carcinoma.


Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Thu, 01 Dec 2011 14:41:00 GMT
A look at the following clinical trial: Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer.


Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Thu, 01 Dec 2011 14:30:00 GMT
A look at the following clinical trial: Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer.


Dutasteride in Treating Patients With Prostate Cancer
Tue, 22 Nov 2011 16:39:46 GMT
A look at the following clinical trial: Dutasteride in Treating Patients With Prostate Cancer.


Quality of Life Study for Prostate Cancer Patients
Tue, 22 Nov 2011 16:38:13 GMT
A look at the following clinical trial: Quality of Life Study for Prostate Cancer Patients.


Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer
Tue, 22 Nov 2011 16:36:26 GMT
A look at the following clinical trial: Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer.


Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer
Mon, 03 Oct 2011 18:22:11 GMT
A look at the following clinical trial: Molecular Correlates of Sensitivity and Resistance to Therapy in Prostate Cancer.


Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance
Mon, 03 Oct 2011 18:20:23 GMT
A look at the following clinical trial: Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance.


High-Intensity Focused Ultrasound in Treating Patients With Localized Prostate Cancer
Mon, 03 Oct 2011 18:18:34 GMT
A look at the following clinical trial: High-Intensity Focused Ultrasound in Treating Patients With Localized Prostate Cancer.


Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Mon, 03 Oct 2011 18:16:25 GMT
A look at the following clinical trial: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer.


Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
Mon, 03 Oct 2011 16:58:27 GMT
A look at the following clinical trial: Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer.


MRI in Diagnosing Prostate Cancer
Mon, 03 Oct 2011 16:56:50 GMT
A look at the following clinical trial: MRI in Diagnosing Prostate Cancer.


Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study
Mon, 03 Oct 2011 16:52:51 GMT
A look at the following clinical trial: Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study.


Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer
Mon, 03 Oct 2011 16:50:47 GMT
A look at the following clinical trial: Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer.


MR Image Guided Therapy in Prostate Cancer
Mon, 03 Oct 2011 16:46:12 GMT
A look at the following clinical trial: MR Image Guided Therapy in Prostate Cancer.


Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. (PCM301)
Thu, 14 Jul 2011 19:06:49 GMT
A look at the following clinical trial: Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance (PCM301).


Prostate Cancer - Qatar (Prostate CA)
Thu, 14 Jul 2011 18:55:36 GMT
A look at the following clinical trial: Prostate Cancer - Qatar (Prostate CA).


Anxiety in Black Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an Sample of Black Men
Tue, 27 Jul 2010 13:34:36 GMT
A look at the following clinical trial: Anxiety in African-American Men With Prostate Cancer: Validation of the Memorial Anxiety Scale for Prostate Cancer in an African-American Sample.


Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
Wed, 17 Mar 2010 16:27:56 GMT
A look at the following clinical trial: Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer.


An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males
Thu, 25 Jun 2009 19:04:17 GMT
A look at the following clinical trial: An Epidemiological Study of Genetic Risk Factors for Prostate Cancer in African-American and Caucasian Males.


Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Fri, 06 Feb 2009 16:24:31 GMT
A look at the following clinical trial: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer.


The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
Tue, 20 Jan 2009 20:27:00 GMT
A look at the following clinical trial: The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older.


Active Surveillance in Prostate Cancer: A Prospective Cohort Study
Tue, 20 Jan 2009 20:25:00 GMT
A look at the following clinical trial: Active Surveillance in Prostate Cancer: A Prospective Cohort Study.


Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Tue, 20 Jan 2009 20:23:00 GMT
A look at the following clinical trial: Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer.


Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone
Fri, 10 May 2013 15:52:00 GMT
A look at the following clinical trial: Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone.


Treatment for Calcium Phosphate Kidney Stone Disease
Fri, 10 May 2013 15:50:00 GMT
A look at the following clinical trial: Treatment for Calcium Phosphate Kidney Stone Disease.


Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients
Fri, 10 May 2013 15:48:00 GMT
A look at the following clinical trial: Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients.


The Impact of Ureteral Stents on Peristalsis
Mon, 31 Dec 2012 14:34:00 GMT
A look at the following clinical trial: The Impact of Ureteral Stents on Peristalsis.


Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis
Mon, 03 Sep 2012 17:14:00 GMT
A look at the following clinical trial: Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis.


"Dusting" Versus "Basketing" - Treatment Of Intrarenal Stones
Mon, 03 Sep 2012 17:13:00 GMT
A look at the following clinical trial: "Dusting" Versus "Basketing" - Treatment Of Intrarenal Stones.


The Importance of Urinary Tract Anatomy and Radiological Parameters in the Extracorporeal Shockwave Lithotripsy Outcomes
Tue, 01 May 2012 17:38:00 GMT
A look at the following clinical trial: The Importance of Urinary Tract Anatomy and Radiological Parameters in the Extracorporeal Shockwave Lithotripsy Outcomes.


Alfuzosin for Medical Expulsion Therapy of Ureteral Stones (MET)
Tue, 01 May 2012 17:35:00 GMT
A look at the following clinical trial: Alfuzosin for Medical Expulsion Therapy of Ureteral Stones (MET).


Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy
Sun, 01 Apr 2012 18:04:00 GMT
A look at the following clinical trial: Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy.


Evaluating Ureteral Length Using Computed Tomography (CT) (URO-Y-2)
Sun, 01 Apr 2012 18:02:00 GMT
A look at the following clinical trial: Evaluating Ureteral Length Using Computed Tomography (CT) (URO-Y-2).


The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers
Thu, 01 Mar 2012 11:00:00 GMT
A look at the following clinical trial: The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers.


Extracorporal Shockwave Lithotripsy Versus Retrograde Intrarenal Surgery for the Treatment of Kidney Stones
Sun, 01 Jan 2012 19:29:00 GMT
A look at the following clinical trial: Extracorporal Shockwave Lithotripsy Versus Retrograde Intrarenal Surgery for the Treatment of Kidney Stones.


Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients
Thu, 01 Dec 2011 15:30:00 GMT
A look at the following clinical trial: Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients.


Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
Thu, 01 Dec 2011 15:27:00 GMT
A look at the following clinical trial: Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis.


Study of the Biological and Physical Manifestations of Spontaneous Uric Acid Kidney Stone Disease (IUAN)
Tue, 22 Nov 2011 15:56:38 GMT
A look at the following clinical trial: Study of the Biological and Physical Manifestations of Spontaneous Uric Acid Kidney Stone Disease (IUAN).


Intraureteral Lidocaine for Post-Ureteroscopy Pain
Tue, 22 Nov 2011 15:52:25 GMT
A look at the following clinical trial: Intraureteral Lidocaine for Post-Ureteroscopy Pain.


Stone Centre Urine and Serum Bank
Tue, 22 Nov 2011 15:49:11 GMT
A look at the following clinical trial: Stone Centre Urine and Serum Bank.


A Pilot Study Assessing The Feasibility Of Outpatient Tubeless Percutaneous Nephrolithotomy (PCNL)
Mon, 03 Oct 2011 15:07:57 GMT
A look at the following clinical trial: A Pilot Study Assessing The Feasibility Of Outpatient Tubeless Percutaneous Nephrolithotomy (PCNL).


Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC
Mon, 03 Oct 2011 15:03:12 GMT
A look at the following clinical trial: Renogram Study With Percutaneous Nephrolithotomy (PERC): Alterations in Renal Blood Flow as a Consequence of PERC.


24 Hour Versus Spot Urine Study
Mon, 03 Oct 2011 14:54:35 GMT
A look at the following clinical trial: 24 Hour Versus Spot Urine Study.


Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery
Fri, 30 Sep 2011 18:41:49 GMT
A look at the following clinical trial: Trial Comparing Three Different Devices for Kidney Stone Removal During Percutaneous Surgery.


Emergency Department Ultrasound in Renal Colic
Thu, 14 Jul 2011 17:48:09 GMT
A look at the following clinical trial: Emergency Department Ultrasound in Renal Colic.


Multicentred, Randomized Control Trial Comparing Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi
Thu, 14 Jul 2011 17:43:57 GMT
A look at the following clinical trial: Multicentred, Randomized Control Trial Comparing Narrow Versus Wide Focal Zones for Shock Wave Lithotripsy of Renal Calculi.


A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members
Thu, 14 Jul 2011 17:24:10 GMT
A look at the following clinical trial: A Clinical Study of the Living Renal Transplantation With Restored Kidneys Between Family Members.


Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation
Tue, 27 Jul 2010 20:09:16 GMT
A look at the following clinical trial: Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation.


New York Area's Largest Hospitals
Fri, 07 Jun 2013 19:27:00 EST
How much did it cost to operate the largest hospitals in the New York area in 2012? Almost 5% more than it did in 2011. Find out just what it takes to make the city's health care facilities run with Crain's list of the New York area's largest hospitals, ranked by 2012 operating expenses.


U.S. Rep. Carolyn McCarthy has lung cancer
Mon, 03 Jun 2013 18:50:00 EST

U.S. Representative Carolyn McCarthy of New York announced Monday she has "a treatable form" of lung cancer.

"A treatment plan will begin soon, and I look forward to its successful completion," the nine-term Democrat from Long Island said in a statement that asked for privacy "while I undergo my treatment."

Ms. McCarthy, 69, said she will be treated at Memorial Sloan-Kettering Cancer Center in New York and will be absent from the House of Representatives during that time.

"I am a fighter, as many people know, and I am committed to beating this latest challenge in my life," she said.

A nurse before her election to the House in 1996, McCarthy has been one of Congress's staunchest supporters of gun control legislation. Her husband was killed and her son was wounded in a mass shooting on the Long Island Rail Road in 1993.




Starbucks to ban smoking within 25 feet of cafes
Fri, 31 May 2013 15:15:00 EST

Starbucks customers will soon have to stamp out their cigarettes before approaching the cafes.

The Seattle-based chain says it will start banning smoking within 25 feet of its stores, beginning Saturday, where permitted by its leases.

Starbucks spokeswoman Jaime Lynn Riley says the intent is to expand the indoor no-smoking policy to the outdoor seating areas.

"If there were any concerns, we would hope to resolve it amicably." Riley said, referring to a customer who might be smoking within the restricted area.

The rule will apply to the 7,000 cafes owned and operated by Starbucks Corp., regardless of whether they have outdoor seating areas.

The policy shouldn't cause a big difference in many areas including New York CIty that already ban smoking within a certain distance of a business entrance.




Montefiore buying 2 Westchester hospitals
Wed, 29 May 2013 15:46:00 EST

Montefiore Medical Center is buying two more hospitals at fire-sale prices, just months after acquiring bankrupt New York Westchester Square Medical Center. Westchester, N.Y.-based Sound Shore Health System will file for Chapter 11 bankruptcy protection. Montefiore announced it will purchase Sound Shore's buildings and other assets, assume certain liabilities and provide funding while Sound Shore is in bankruptcy proceedings. Montefiore plans to keep open and operate Sound Shore's two hospitals in Mount Vernon and New Rochelle, as well as its nursing home.

The proposed transaction needs bankruptcy court and New York state Department of Health approvals. Sound Shore and Montefiore did not disclose financial details of the transaction, which they said could be completed by the end of the year.

In a statement, Montefiore CEO Dr. Steven Safyer said his hospital "looks forward to building on our existing clinical presence in lower Westchester and working with the dedicated doctors, nurses and staff of Sound Shore and Mount Vernon hospitals and the Schaffer Extended Care Center who have served their patients well over many years."

Montefiore already operates nine health clinics in Westchester.

Earlier in May, negotiations between Westchester Medical Center and the Sound Shore Health System broke off after Westchester Medical ended the merger talks.

"Sound Shore appears to have a dramatically different view than WMC about how to best balance resources between investment in improving the Sound Shore/Mount Vernon facilities and the obligations that the Sound Shore System has accumulated over the years," Westchester Medical said in a statement announcing the deal was off.

It added that it was "prepared to dedicate enormous resources to the effort to keep these clinical sites open and upgrade them to better serve New Rochelle, Mount Vernon and the surrounding communities," but would now pursue alternatives to a merger to meet their health care needs.

The Sound Shore system was facing a $3 million to $5 million year-end loss when talks with Westchester Medical began in December.




SUNY officials call for new Brooklyn health network
Wed, 29 May 2013 15:16:00 EST

State University of New York officials Tuesday unveiled a plan to keep their treasured Brooklyn medical school afloat by creating a new integrated health network in the borough.

Financially-strapped SUNY Downstate Medical Center faced a June 1 legislative deadline to submit a sustainability plan to the state health and budget departments, for implementation by June 15.

Downstate's goal has been to preserve its medical school, which SUNY officials said holds a unique position in how it trains minority doctors that tend to stay in New York, and in Brooklyn itself, to practice medicine. To meet that goal, they acknowledged that the school's teaching hospital, University Hospital of Brooklyn, must downsize, and its Long Island College Hospital campus must be jettisoned.

Downstate isn't the only Brooklyn hospital struggling to adapt to a changing health care industry. More health care is being delivered outside of hospitals, in clinics, outpatient centers and doctors' offices, at the same time that health care reforms have brought cuts in state and federal aid.

"We know we're not alone," said Lora Lefebvre, associate vice chancellor for health affairs at SUNY, speaking of the financial pressure on Brooklyn hospitals.

And so SUNY is proposing a new Brooklyn integrated health network. The consortium of academic and clinical providers would collectively negotiate better managed-care reimbursement, collaborate on improving the quality of care while reducing costs. Ms. Lefebvre said the idea of an integrated network was first proposed by the state's Medicaid Redesign Team's Brooklyn task force.

SUNY officials suggested a new way of corralling Brooklyn health care providers to work together. A public benefit corporation would be established to spearhead health initiatives in Brooklyn, including promoting the creation of a clinically-integrated provider network. But the corporation would neither run hospitals or a health network itself.

In the short term, SUNY officials have proposed a two-step plan: first downsize University Hospital, and then restructure operations with hundreds of millions of dollars in state aid.

In the meantime, Downstate will address inefficiencies like rightsizing lengths of stay and improving spotty bill collection. University Hospital "will become smaller," said Ms. Lefebvre, but will not close.

As for LICH, the Cobble Hill hospital that has been the target of a lawsuit aimed at blocking its closure, responses were due on May 24 from entities expressing interest in operating some form of health facility there. Ms. Lefebvre said SUNY received credible responses.

"Some proposals looked great," she said, declining to provide details on the submissions. "I'm cautiously optimistic."

SUNY's sustainability plan includes financial projections related to ending its operation of LICH. The exit plan requires about $129 million in state funding over four fiscal years. Restructuring at University Hospital would require an additional $225 million.

Ms. Lefebvre said, however, that there were no assurances that SUNY will get the state aid. "We were asked to identify what we needed, and we did," she said.

New York State has long hoped that it would get a waiver it requested last August from the federal government to re-invest up to $10 billion in Medicaid savings. But federal officials have not yet granted the request. "Without this waiver, areas throughout New York will face severe consequences," Gov. Andrew Cuomo wrote on May 7 to U.S. Department of Health and Human Services Secretary Kathleen Sebelius. "Nowhere is the situation more critical than in Brooklyn," where a "rapid deterioration" in the finances of the borough's health system could lead to the closure of at least four hospitals.

An outline of Downstate's sustainability plan is online here.




NY's biggest companies, by the numbers
Sun, 26 May 2013 00:01:00 EST

As a whole, 2012 treated New York pretty well. The city added 76,000 jobs, New York Stock Exchange members posted profits triple 2011 levels and now, according to Crain's research, 71% of the area's top publicly traded companies posted gains in revenue.

At the area's top 250 publicly traded companies, revenue was up 3.7% between 2011 and 2012 to $1.68 trillion—just shy of Canada's gross domestic product—according to research from S&P Capital IQ provided to Crain's. It was led by gains in the financial services sector. Eight of the 15 fastest growing companies on the list—including Apollo Global Management, which posted growth of 1,566.3%, and Leucadia National Corp.—are a part of that industry.

Click here to download the entire list of the largest publicly held companies in the New York area.




NY's top public firms rival Canada's GDP
Fri, 24 May 2013 13:45:00 EST

If the top publicly held companies in the New York area joined forces as a country, it would rival Canada.

Revenue at the 250 largest publicly held companies was $1.68 trillion in 2012, up 3.7% from a year earlier. The Great White North posted a gross domestic product of $1.77 trillion. Financial service firms accounted for more than a third of the New York figure—or nearly the GDP of Saudi Arabia—according to research S&P Capital IQ provided to Crain's.

Click here to download the entire list of the largest publicly held companies in the New York area.




Johnson & Johnson plans 10 new drug applications
Thu, 23 May 2013 09:19:00 EST
Johnson & Johnson plans 10 new drug applications

Johnson & Johnson says it plans to submit more than 10 new treatments to regulators for approval and 25 applications for additional uses of approved drugs by 2017.

The New Brunswick, N.J., company says its pipeline of drugs in late-stage clinical development include a potential hepatitis C treatment being reviewed by regulars, a version of the anti-psychotic Invega designed to last three months and new vaccines for flu, rabies and polio.

Johnson & Johnson makes prescription drugs, consumer health products and medical devices.

It says its pharmaceuticals segment has launched 11 new products since 2009. They made up 17% of total pharmaceutical sales last year, which is up from 9% in 2011. These products include the blood thinner Xarelto, Invega and J&J's first diabetes treatment, Invokana.




Post-debate, Weiner responds
Wed, 22 May 2013 15:43:00 EST
Post-debate, Weiner responds

Anthony Weiner has a message for the business community: Ignore the scandal, focus on the ideas.

In a 14-minute phone interview with The Insider hours after he formally kicked off his improbable campaign with a video posted online in the dead of night, Mr. Weiner touched on everything from health care to rezoning to project labor agreements, and repeated his request that voters, and especially the business community, look closely at his policy platform before determining whether he has earned a second chance for their support.

"What I'm going to try to say to business interests, to union interests, to citizens on the street, is take a look at the ideas I'm talking about," Mr. Weiner said. "There may be people in New York who would never vote for me again. I even want to have this conversation with them."

Mr. Weiner said he understands that there are some who will only want to discuss his "private failings," a reference to the sexting scandal that pushed him out of office two years ago. Nevertheless, he said he hoped to pivot to a discussion of ideas, many of which touch on the spiraling costs of health care, a subject he spoke about frequently and loudly while in Congress.

He declined to rate Mayor Michael Bloomberg's tenure in office on a scale from 1 to 10, a question that was asked of his fellow Democratic candidates during a debate hosted by Crain's Wednesday morning. (Mr. Weiner apologized for his absence. Bill de Blasio also did not attend.)

He said Mr. Bloomberg had achieved some "laudable" goals while in office, citing the PlaNYC 2030 sustainability plan and his efforts to reduce racial tension in the city. But he contested job growth figures under the mayor, noting that it is a "cause for concern" that so many of the jobs created have been low-wage, low-skill positions.

He said if elected, he would tackle one of the big "existential budgetary problems in the city" and a "big business drag" on the economy: the high cost of health care. The city spends around $14 billion on it, or around 20% of the budget, which Mr. Weiner said was unsustainable.

"I've got a proposal that I'll be fleshing out in the months to come that basically says, 'Look, there's got to be a more efficient way to spend that $14 billion that would drive the health care economy in a more efficient way, and keep more of the revenue generated from the health care economy here in New York City rather than go to someplace else,'" he said. "These are things that haven't been explored much on the campaign trail."

Like the other candidates, Mr. Weiner declined to discuss in detail his position on the expired labor contracts with the city's municipal workforce, but did hint at how he'd approach the approximately $4 billion in retroactive raises sought by the unions.

"I will say this: It is unsustainable and wrong that 90% of city employees pay nothing in health care premiums," he said, echoing a sentiment often expressed by Mr. Bloomberg and fiscal watchdog groups, not to mention some of the Republican mayoral candidates. "I think that needs to change, and it doesn't need to be much."

He added, "I'm going to try to make the case to city workers that right now, every dime that could be used for wages is being eaten up by health care costs, and to some extent pension costs."

He called the city's paid sick leave and living wage laws "good initiatives…in a small-bore way" that may not go far enough in protecting workers.

"I believe it's a laudable objective," he said. "While these bills were not what I would like ideally—I have my own proposals on health care—I think we need to find ways to help care for their children…by giving them reasonable accommodations at work."

Mr. Weiner said he did not object to unions and contractors hashing out project labor agreements on construction projects, but that he did have some worry about the outcome of such agreements.

"I am concerned about the notion that we're having one-off auctions that don't do a good enough job stating what city policy should be," he said. "I think it's perfectly fair and reasonable, in exchange for a public resource like air rights, to say we want certain benefits for the community. I would feel much more comfortable if it was done in an open and transparent way with the city trying to quarterback the thing, rather than have private interests negotiating behind closed doors, and creating a silent auction of activity."

Finally, addressing the massive number of rezonings under Mr. Bloomberg's watch, Mr. Weiner stressed the need for diversity.

"I'm concerned that we rezoned so much during the housing bubble that we left out opportunities for things like light manufacturing and small business jobs that we see move to places like Jersey City," he said. "When you do planning, we can't just be planning for the opportunities we see, we also need to plan for the opportunities we want to see."

He added, "We can't have an economy that's white rice, we have to have one that's Pad Thai—we have to have an economy that has a little bit of everything."




City's job juggernaut rolls on
Mon, 20 May 2013 11:31:00 EST

The headline on last week's report on jobs was that city's unemployment rate had fallen sharply to a four-year low. That is good news of course, but that most unreliable statistics on the city's economy is actually less important than the strong jobs performance.

The city gained 45,000 jobs in the first four months, according to the seasonally adjusted report from Eastern Consolidated, putting New York on track for an increase this year of 100,000, which is close to the record. If it happens, Mayor Michael Bloomberg will leave office with the city boasting more than 4 million workers—or 345,000 more than when he took office—despite two serious recessions.

Here are two charts that show how strong the jobs recovery has been in New York compared with the rest of the country.

Here are two charts that show how strong the jobs recovery has been in New York compared with the rest of the country.

Location% jobs gained since 2009
NYC7.5%
US4.8%
Location% jobs gained/lost since 2008 peak
NYC138,500
US-2,030,000

Source: Eastern Consolidated

The knock on the jobs increase is that these are all low wage jobs. Below are the areas that have gained the most jobs since the recovery.